Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors

被引：0
|
作者：
Gallois, Claire
Landi, Matteo
Taieb, Julien
Lonardi, Sara
Bergamo, Francesca
Intini, Rossana
Maddalena, Giulia
Pietrantonio, Filippo
Corti, Francesca
Ambrosini, Margherita
Martinetti, Antonia
Germani, Marco Maria
Boccaccio, Chiara
Vetere, Guglielmo
Mouillet-Richard, Sophie
de Reynies, Aurelien
Puig, Pierre Laurent
Cremolini, Chiara
机构：
[1] Univ Paris Cite, Inst Canc Paris CARPEM, Digest Oncol Dept, Hop Europeen G Pompiduo, Paris, France
[2] Univ Pisa, Pisa, Italy
[3] Univ Paris, Dept Gastroenterol & Gastrointestinal Oncol, Hop Europeen Georges Pompidou, AP HP, Paris, France
[4] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Padua, Italy
[5] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Med Oncol 1, Padua, Italy
[6] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Med Oncol 1, Padua, Italy
[7] Ist Oncol Veneto IOV IRCCS, Oncol Unit 1, Padua, Italy
[8] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy
[9] IRCCS Fdn Natl Canc Inst, Milan, Italy
[10] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[11] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[12] Univ Paris Cite, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France
[13] Inst Canc Paris CARPEM, Dept Biol, Hop Europeen Georges Pompidou, APHP Ctr, Paris, France
[14] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[15] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3570
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
    Gallois, Claire
    Landi, Matteo
    Taieb, Julien
    Sroussi, Marine
    Saberzadeh-Ardestani, Bahar
    Cazelles, Antoine
    Lonardi, Sara
    Bergamo, Francesca
    Intini, Rossana
    Maddalena, Giulia
    Pietrantonio, Filippo
    Corti, Francesca
    Ambrosini, Margherita
    Martinetti, Antonia
    Germani, Marco Maria
    Boccaccio, Chiara
    Vetere, Guglielmo
    Mouillet-Richard, Sophie
    de Reynies, Aurelien
    Sinicrope, Frank A.
    Cremolini, Chiara
    Laurent-Puig, Pierre
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3771 - 3778
  • [2] Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer
    Okamoto, W.
    Nakamura, Y.
    Shiozawa, M.
    Komatsu, Y.
    Denda, T.
    Hara, H.
    Kagawa, Y.
    Narita, Y.
    Kawakami, H.
    Esaki, T.
    Nishina, T.
    Izawa, N.
    Ando, K.
    Moriwaki, T.
    Kato, T.
    Nagashima, F.
    Satoh, T.
    Nomura, S.
    Yoshino, T.
    Akagi, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
    Schrock, A. B.
    Ouyang, C.
    Sandhu, J.
    Sokol, E.
    Jin, D.
    Ross, J. S.
    Miller, A.
    Lim, D.
    Amanam, I
    Chao, J.
    Catenacci, D.
    Cho, M.
    Braiteh, F.
    Klempner, S. J.
    Ali, S. M.
    Fakih, M.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1096 - 1103
  • [4] Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.
    Okamoto, Wataru
    Nakamura, Yoshiaki
    Shiozawa, Manabu
    Komatsu, Yoshito
    Denda, Tadamichi
    Hara, Hiroki
    Kagawa, Yoshinori
    Narita, Yukiya
    Kawakami, Hisato
    Esaki, Taito
    Nishina, Tomohiro
    Izawa, Naoki
    Ando, Koji
    Moriwaki, Toshikazu
    Kato, Takeshi
    Nagashima, Fumio
    Satoh, Taroh
    Nomura, Shogo
    Yoshino, Takayuki
    Akagi, Kiwamu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
    Roth, Marc T.
    Das, Satya
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (02) : 229 - 238
  • [6] Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study
    Hulst, L.
    Cappuyns, S.
    Peeters, F.
    Vulsteke, F.
    Van Herpe, F.
    Van Cutsem, E.
    Dekervel, J.
    CLINICAL COLORECTAL CANCER, 2024, 23 (03)
  • [7] Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
    Bui, Quang Loc
    Mas, Leo
    Hollebecque, Antoine
    Tougeron, David
    de la Fouchardiere, Christelle
    Pudlarz, Thomas
    Alouani, Emily
    Guimbaud, Rosine
    Taieb, Julien
    Andre, Thierry
    Colle, Raphael
    Cohen, Romain
    CANCERS, 2022, 14 (02)
  • [8] Case of Two Patients with MSI-High Metastatic Colorectal Cancer Treated with Pembrolizumab
    Kurreck, Annika
    Stintzing, Sebastian
    Modest, Dominik Paul
    Jelas, Ivan
    von Einem, Jobst C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 50 - 50
  • [9] Distinctive Tumor Biology of MSI-High Colorectal Cancer
    Majithia, Neil
    Kipp, Benjamin R.
    Grothey, Axel
    CURRENT COLORECTAL CANCER REPORTS, 2015, 11 (05) : 281 - 287
  • [10] Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer
    Heregger, Ronald
    Huemer, Florian
    Steiner, Markus
    Gonzalez-Martinez, Alejandra
    Greil, Richard
    Weiss, Lukas
    CANCERS, 2023, 15 (20)
12345